DUBLIN--(BUSINESS WIRE)--The "Dry Eye Syndrome: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024" report has been added to ResearchAndMarkets.com's offering.
The report predicts the global dry eye syndrome to grow with a CAGR of 4.8% over the forecast period of 2018-2024.
The growth of the dry eye syndrome market is majorly due to combination of factors such as rising geriatric population around the world, growing prevalence of diabetes and increase awareness among the population concerning dry eye syndrome. However, Dry eye syndrome is likely to be ignored by many patients, since the inconvenience caused by it is not debilitating which affects the market growth. The rising awareness about the dry eye syndrome diagnosis & treatment can result in more number of patients proactively trying to cure the disease that may create lucrative opportunities for market growth.
The dry eye syndrome market is influenced mainly by North America region in 2017. The high prevalence of lifestyle disorders that increases the chances of contracting dry eye syndrome in this region is a major driver for the North America dry eye syndrome market. Asia Pacific is expected to grow at the highest CAGR during the forecast period owing to growing healthcare infrastructure facilities and increasing population that is likely to increase the chance of people getting affected with dry eye syndrome.
- Novartis AG
- Allergan plc
- Otsuka Holdings Co
- Santen Pharmaceutical Co.Ltd
- Nicox S.A.
- Auven Therapeutics
- Akorn, Inc.
- Bausch & Lomb Incorporated
- Alimera Science
- GlaxoSmithKline plc
Key Topics Covered:
2. Executive Summary
3. Global Dry Eye Syndrome Market Overview
4. Global Dry Eye Syndrome Market by Drug
5. Global Dry Eye Syndrome Market by Product
6. Global Dry Eye Syndrome Market by Region 2018-2024
7. Company Covered
For more information about this report visit https://www.researchandmarkets.com/research/4bbf9r/global_dry_eye?w=4